Clinical Application of M6A in Cervical Cancer and Precancerous Lesions
DOI:
https://doi.org/10.18063/apm.v10i2.869Keywords:
Cervical cancer, m6A, Methylation, Precancerous lesionAbstract
N6-methyladenosine (m6A) is a key epigenetic modification in eukaryotic RNA. Studies in cervical cancer reveal that m6A levels and its modifying enzymes may serve as promising molecular markers for tumor progression monitoring and precision diagnosis. This paper aims to explore the relationship between Writer (methyltransferase), ERASERS (desmethyltransferase), Readers (recognition proteins) and cervical cancer cell molecules In m6A methylation modification, which are the regulators of m6A methylation modification, to provide new perspectives and strategies for the clinical diagnosis and treatment of pre-cancerous cervical lesions and cervical cancer. Modulating its expression in vivo may enhance cervical cancer cells’ radiotherapy sensitivity, potentially addressing chemotherapy resistance and improving therapeutic outcomes for advanced-stage cases.
References
Volkova LV, Pashov AI, Omelchuk NN, 2021, Cervical Carcinoma: Oncobiology and Biomarkers. International Journal of Molecular Sciences, 22(22): 12571.
Singh D, Vignat J, Lorenzoni V, et al., 2023, Global Estimates of Incidence and Mortality of Cervical Cancer in 2020: A Baseline Analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health, 11(2): e197–e206.
Mao Z, Wang B, Zhang T, et al., 2023, The Roles of m6A Methylation in Cervical Cancer: Functions, Molecular Mechanisms, and Clinical Applications. Cell Death & Disease, 14(11): 734.
Wang X, Li Z, Kong B, et al., 2017, Reduced m(6)A mRNA Methylation Is Correlated with the Progression of Human Cervical Cancer. Oncotarget, 8(58): 98918–98930.
Ma X, Li Y, Wen J, et al., 2020, m6A RNA Methylation Regulators Contribute to Malignant Development and Have a Clinical Prognostic Effect on Cervical Cancer. American Journal of Translational Research, 12(12): 8137–8146.
Zhuo W, Sun M, Wang K, et al., 2022, m(6)Am Methyltransferase PCIF1 Is Essential for Aggressiveness of Gastric Cancer Cells by Inhibiting TM9SF1 mRNA Translation. Cell Discovery, 8(1): 48.
Boccaletto P, Machnicka MA, Purta E, et al., 2018, MODOMICS: A Database of RNA Modification Pathways. 2017 Update. Nucleic Acids Research, 46(D1): D303–D307.
Wei CM, Gershowitz A, Moss B, 1975, Methylated Nucleotides Block 5’ Terminus of HeLa Cell Messenger RNA. Cell, 4(4): 379–386.
Desrosiers R, Friderici K, Rottman F, 1974, Identification of Methylated Nucleosides in Messenger RNA from Novikoff Hepatoma Cells. Proceedings of the National Academy of Sciences, 71(10): 3971–3975.
Ji H, Zhang JA, Liu H, et al., 2022, Comprehensive Characterization of Tumor Microenvironment and m6A RNA Methylation Regulators and Its Effects on PD-L1 and Immune Infiltrates in Cervical Cancer. Frontiers in Immunology, 13: 976107.
He L, Li H, Wu A, et al., 2019, Functions of N6-Methyladenosine and Its Role in Cancer. Molecular Cancer, 18(1): 176.
Bokar JA, Shambaugh ME, Polayes D, et al., 1997, Purification and cDNA Cloning of the AdoMet-Binding Subunit of the Human mRNA (N6-Adenosine)-Methyltransferase. RNA, 3(11): 1233–1247.
Liu J, Yue Y, Han D, et al., 2014, A METTL3-METTL14 Complex Mediates Mammalian Nuclear RNA N6-Adenosine Methylation. National Chemical Biology, 10(2): 93–95.
Wang X, Feng J, Xue Y, et al., 2016, Structural Basis of N(6)-Adenosine Methylation by the METTL3-METTL14 Complex. Nature, 534(7608): 575–578.
Wang P, Doxtader KA, Nam Y, 2016, Structural Basis for Cooperative Function of METTL3 and METTL14 Methyltransferases. Molecular Cell, 63(2): 306–317.
Huang J, Dong X, Gong Z, et al., 2019, Solution Structure of the RNA Recognition Domain of METTL3-METTL14 N(6)-Methyladenosine Methyltransferase. Protein Cell, 10(4): 272–284.
Hu C, Liu T, Xu Y, et al., 2022, METTL14 Promotes the Proliferation and Migration of Cervical Cancer Cells by Up-Regulating m(6)A Myc Expression. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 38(2): 131–137.
Xie Q, Li Z, Luo X, et al., 2022, piRNA-14633 Promotes Cervical Cancer Cell Malignancy in a METTL14-Dependent m6A RNA Methylation Manner. Journal of Translational Medicine, 20(1): 51.
Ping XL, Sun BF, Wang L, et al., 2014, Mammalian WTAP Is a Regulatory Subunit of the RNA N6-Methyladenosine Methyltransferase. Cell Research, 24(2): 177–189.
Zhu K, Li Y, Xu Y, 2021, The FTO m(6)A Demethylase Inhibits the Invasion and Migration of Prostate Cancer Cells by Regulating Total m(6)A Levels. Life Science, 271: 119180.
Azzam SK, Alsafar H, Sajini AA, 2022, FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms. International Journal of Molecular Science, 23(7).
Jia GF, Fu Y, Zhao X, et al., 2011, N6-Methyladenosine in Nuclear RNA Is a Major Substrate of the Obesity-Associated FTO. Nature Chemical Biology, 7(12): 885–887.
Zheng GQ, Dahl JA, Niu YM, et al., 2013, ALKBH5 Is a Mammalian RNA Demethylase That Impacts RNA Metabolism and Mouse Fertility. Molecular Cell, 49(1): 18–29.
Xu C, Wang X, Liu K, et al., 2014, Structural Basis for Selective Binding of m6A RNA by the YTHDC1 YTH Domain. National Chemical Biology, 10(11): 927–929.
Xiao W, Adhikari S, Dahal U, et al., 2016, Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Molecular Cell, 61(4): 507–519.
Zhang L, Wan YC, Zhang ZH, et al., 2021, IGF2BP1 Overexpression Stabilizes PEG10 mRNA in an m6A-Dependent Manner and Promotes Endometrial Cancer Progression. Theranostics, 11(3): 1100–1114.
Liu T, Wei QL, Jin J, et al., 2020, The m6A Reader YTHDF1 Promotes Ovarian Cancer Progression via Augmenting EIF3C Translation. Nucleic Acids Research, 48(7): 3816–3831.
Mersakova S, Nachajova M, Szepe P, et al., 2016, DNA Methylation and Detection of Cervical Cancer and Precancerous Lesions Using Molecular Methods. Tumour Biology, 37(1): 23–27.
Bowden SJ, Kalliala I, Veroniki AA, et al., 2019, The Use of Human Papillomavirus DNA Methylation in Cervical Intraepithelial Neoplasia: A Systematic Review and Meta-Analysis. EBioMedicine, 50: 246–259.
Kong L, Wang L, Wang Z, et al., 2023, Cytological DNA Methylation for Cervical Cancer Screening: A Validation Set. Frontiers in Oncology, 13: 1181982.
Dankai W, Khunamornpong S, Siriaunkgul S, et al., 2019, Role of Genomic DNA Methylation in Detection of Cytologic and Histologic Abnormalities in High Risk HPV-Infected Women. PLoS One, 14(1): e210289.
Kremer WW, Steenbergen R, Heideman D, et al., 2021, The Use of Host Cell DNA Methylation Analysis in the Detection and Management of Women with Advanced Cervical Intraepithelial Neoplasia: A Review. BJOG, 128(3): 504–514.
Zhang W, Xiao P, Tang J, et al., 2022, m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment. Frontiers in Immunology, 13: 888650.
Ao K, Yin M, Lyu X, et al., 2024, METTL3-Mediated HSPA9 m6A Modification Promotes Malignant Transformation and Inhibits Cellular Senescence by Regulating Exosomal Mortalin Protein in Cervical Cancer. Cancer Letter, 587: 216658.
Liang L, Zhu Y, Li J, et al., 2022, ALKBH5-Mediated m6A Modification of circCCDC134 Facilitates Cervical Cancer Metastasis by Enhancing HIF1A Transcription. Journal of Experimental and Clinical Cancer Research, 41(1): 261.
Elcheva IA, Wood T, Chiarolanzio K, et al., 2020, RNA-Binding Protein IGF2BP1 Maintains Leukemia Stem Cell Properties by Regulating HOXB4, MYB, and ALDH1A1. Leukemia, 34(5): 1354–1363.
Li N, Kang Y, Wang L, et al., 2020, ALKBH5 Regulates Anti-PD-1 Therapy Response by Modulating Lactate and Suppressive Immune Cell Accumulation in Tumor Microenvironment. Proceedings of National Academy Science, 117(33): 20159–20170.
He X, Tan L, Ni J, et al., 2021, Expression Pattern of m(6)A Regulators Is Significantly Correlated with Malignancy and Antitumor Immune Response of Breast Cancer. Cancer Gene Therapy, 28(3–4): 188–196.
Ji F, Lu Y, Chen S, et al., 2021, mA Methyltransferase METTL3-Mediated lncRNA FOXD2-AS1 Promotes the Tumorigenesis of Cervical Cancer. Molecular Therapy Oncolytics, 22: 574–581.
Zhang B, Wu Q, Li B, et al., 2020, m(6)A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Gastric Cancer. Molecular Cancer, 19(1): 53.
Li M, Zha X, Wang S, 2021, The Role of N6-Methyladenosine mRNA in the Tumor Microenvironment. Biochimica et Biophysica Acta, 1875(2): 188522.
Guo Y, Bai Y, Wang L, et al., 2022, The Significance of m6A RNA Methylation Modification in Prognosis and Tumor Microenvironment Immune Infiltration of Cervical Cancer. Medicine, 101(26): e29818.
Vander HM, Cantley LC, Thompson CB, 2009, Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science, 324(5930): 1029–1033.
Schwartz L, Supuran CT, Alfarouk KO, 2017, The Warburg Effect and the Hallmarks of Cancer. Anti-Cancer Agents in Medicinal Chemistry, 17(2): 164–170.
Wang Q, Guo X, Li L, et al., 2020, N(6)-Methyladenosine METTL3 Promotes Cervical Cancer Tumorigenesis and Warburg Effect Through YTHDF1/HK2 Modification. Cell Death Discovery, 11(10): 911.
Hu C, Liu T, Han C, et al., 2022, HPV E6/E7 Promotes Aerobic Glycolysis in Cervical Cancer by Regulating IGF2BP2 to Stabilize m(6)A-MYC Expression. International Journal of Biological Science, 18(2): 507–521.
Yang Z, Ma J, Han S, et al., 2020, ZFAS1 Exerts an Oncogenic Role via Suppressing miR-647 in an m(6)A-Dependent Manner in Cervical Cancer. Oncology Targets Therapy, 13: 11795–11806.
Yuan Y, Cai X, Shen F, et al., 2021, HPV Post-Infection Microenvironment and Cervical Cancer. Cancer Letters, 497: 243–254.
Fc H, Zm Z, Du WQ, et al., 2023, HPV E7-Drived ALKBH5 Promotes Cervical Cancer Progression by Modulating m6A Modification of PAK5. Pharmacological Research, 195: 106863.
Du QY, Fc H, Du WQ, et al., 2022, METTL3 Potentiates Progression of Cervical Cancer by Suppressing ER Stress via Regulating m6A Modification of TXNDC5 mRNA. Oncogene, 41(39): 4420–4432.
Wang H, Luo Q, Kang J, et al., 2021, YTHDF1 Aggravates the Progression of Cervical Cancer Through m(6)A-Mediated Up-Regulation of RANBP2. Frontiers in Oncology, 11: 650383.
Zhu P, Tan Q, Jiang W, et al., 2019, Eukaryotic Translation Initiation Factor 3B Is Overexpressed and Correlates with Deteriorated Tumor Features and Unfavorable Survival Profiles in Cervical Cancer Patients. Cancer Biomarker, 26(2): 123–130.
